4547 — Kissei Pharmaceutical Co Income Statement
0.000.00%
- ¥158bn
- ¥116bn
- ¥76bn
- 73
- 39
- 85
- 76
Annual income statement for Kissei Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 63,234 | 69,044 | 65,381 | 67,493 | 75,579 |
Cost of Revenue | |||||
Gross Profit | 34,894 | 32,723 | 31,238 | 32,375 | 37,341 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 62,179 | 66,893 | 67,223 | 68,556 | 71,257 |
Operating Profit | 1,055 | 2,151 | -1,842 | -1,063 | 4,322 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4,630 | 7,476 | 16,507 | 13,680 | 14,449 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2,889 | 5,378 | 13,032 | 10,634 | 11,290 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 2,818 | 5,285 | 12,922 | 10,529 | 11,162 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2,817 | 5,285 | 12,921 | 10,528 | 11,160 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 71.5 | 103 | 288 | 226 | 240 |
Dividends per Share |